What do systematic reviews say?

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Drugs for preventing red blood cell dehydration in people with sickle cell disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 524 participants
  Low

Epoetin alpha every 2 weeks vs to weekly

Epoetin alpha every 2 weeks showed no clear difference in number of deaths compared with to weekly (low certainty).

• Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
  RR 0.89 [0.38, 2.07]
  4 studies · 838 participants
  Low

Epoetin alfa every four weeks vs with every two weeks

Epoetin alfa every four weeks showed no clear difference in number of deaths compared with with every two weeks (low certainty).

• Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
  RR 0.95 [0.33, 2.75]
  3 studies · 724 participants
  Low

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in deaths Number of deaths compared with placebo (moderate certainty).

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  RR 0.84 [0.52, 1.34]
  1 study · 304 participants
  Moderate

Intervention not reported

• Antiepileptic drugs as prophylaxis for postcraniotomy seizures 2020 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1016 participants
  Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in survival: number of deaths compared with tobramycin (low certainty).

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  RR 0.21 [0.01, 4.32]
  1 study · 374 participants
  Low

Summary of findings: tobramycin for inhalation powder vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  4.76 [0.25, 91.62]
  1 study · 517 participants
  Low

Summary of findings: anti‐pseudomonal antibiotics vs placebo

Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in survival: number of deaths compared with placebo (low certainty).

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  RR 0.17 [0.03, 1.09]
  2 studies · 767 participants
  Low

Intervention not reported

• Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Low

Intervention not reported

• International travel‐related control measures to contain the COVID‐19 pandemic: a rapid review 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Home‐based vs centre‐based cardiac rehabilitation

Home‐based showed no clear difference in total mortality Number of deaths compared with centre‐based cardiac rehabilitation (low certainty).

• Home‐based versus centre‐based cardiac rehabilitation 2023 · Cochrane Headline outcomes only
  RR 1.19 [0.65, 2.16]
  12 studies · 1647 participants
  Low

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in death Number of deaths over 36 months compared with placebo (moderate certainty).

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  RR 1.01 [0.3, 3.44]
  1 study · 516 participants
  Moderate

Ruxolitinib vs placebo

Ruxolitinib may leads to lower overall survival (number of deaths at compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  HR 0.51 [0.27, 0.98]
  1 study · 309 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib showed no clear difference in overall survival (number of deaths at compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  HR 0.7 [0.2, 2.47]
  1 study · 219 participants
  Low

Case management vs usual care

Case management showed no clear difference in mortality (number of deaths) at 12 months compared with usual care (high certainty).

• Case management approaches to home support for people with dementia 2015 · Cochrane Headline outcomes only
  OR 1 [0.83, 1.2]
  8 studies · 6112 participants
  High